series-c-plus
Stage
2003
Founded
2
Investors
About
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based nanotherapeutics to revolutionize treatment outcomes for millions of patients with cancer and other challenging diseases. Its lead candidate NBTXR3 is a potential first-in-class radioenhancer designed to increase the dose of radiotherapy absorbed by tumor cells without increasing the dose in surrounding healthy tissues.
Explore Nanobiotix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.